Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study
Susana Banerjee, Alvaro Ingles Russo Garces, Jamie Garside, Tameera Rahman, Clare Pearson, Kiera Heffernan · 2024
Read Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study by Susana Banerjee, Alvaro Ingles Russo Garces, Jamie Garside, Tameera Rahman, Clare Pearson, Kiera Heffernan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590861.txt.
Description
Susana Banerjee and co-authors describe real-world outcomes for advanced womb cancer in England in a 2024 study. The cancer, of the lining of the womb, often returns after first treatment and then has few good options. New immune drugs are being tested for first-line use, and trial results need a real-world baseline for comparison.
Using national registry data, the team built a cohort of patients who would likely have qualified for a major immune drug trial. Median survival after first treatment was about twenty-seven months. In the subgroup treated only with a standard two-drug chemotherapy, survival was much shorter, at about seventeen months. Treatment was stopped after a few months in both groups. The authors say the poor outcomes show the need for more durable therapies.
Catalog record
| CREATOR | Susana Banerjee, Alvaro Ingles Russo Garces, Jamie Garside, Tameera Rahman, Clare Pearson, Kiera Heffernan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |